• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Chem Senses . Six-month psychophysical evaluation of olfactory dysfunction in patients with COVID-19

tetano

Editor, Senior Moderator
Chem Senses


. 2021 Feb 12;bjab006.
doi: 10.1093/chemse/bjab006. Online ahead of print.
Six-month psychophysical evaluation of olfactory dysfunction in patients with COVID-19


Paolo Boscolo-Rizzo[SUP] 1 [/SUP], Anna Menegaldo[SUP] 2 [/SUP], Cristoforo Fabbris[SUP] 2 [/SUP], Giacomo Spinato[SUP] 2 [/SUP], Daniele Borsetto[SUP] 3 [/SUP], Luigi Angelo Vaira[SUP] 4 [/SUP], Leonardo Calvanese[SUP] 2 [/SUP], Andrea Pettorelli[SUP] 2 [/SUP], Massimo Sonego[SUP] 2 [/SUP], Daniele Frezza[SUP] 2 [/SUP], Andy Bertolin[SUP] 5 [/SUP], Walter Cestaro[SUP] 6 [/SUP], Roberto Rigoli[SUP] 7 [/SUP], Andrea D'Alessandro[SUP] 1 [/SUP], Giancarlo Tirelli[SUP] 1 [/SUP], Maria Cristina Da Mosto[SUP] 2 [/SUP], Anna Menini[SUP] 8 [/SUP], Jerry Polesel[SUP] 9 [/SUP], Claire Hopkins[SUP] 10 [/SUP]



Affiliations

Abstract

This study prospectively assessed the six-month prevalence of self-reported and psychophysically measured olfactory dysfunction in subjects with mild-to-moderate COVID-19. Self-reported smell or taste impairment was prospectively evaluated by SNOT-22 at diagnosis, 4-week, 8-week, and 6-month. At 6 months from the diagnosis, psychophysical evaluation of olfactory function was also performed using the 34-item culturally adapted University of Pennsylvania Smell Identification Test (CA-UPSIT). 145 completed both the 6-month subjective and psychophysical olfactory evaluation. According to CA-UPSIT, 87 subjects (60.0%) exhibited some smell dysfunction, with 10 patients being anosmic (6.9%) and 7 being severely microsmic (4.8%). At the time CA-UPSIT was administered, a weak correlation was observed between the self-reported alteration of sense of smell or taste and olfactory test scores (Spearman's r=-0.26). Among 112 patients who self-reported normal sense of smell at last follow-up, CA-UPSIT revealed normal smell in 46 (41.1%), mild microsmia in 46 (41.1%), moderate microsmia in 11 (9.8%), severe microsmia in 3 (2.3%), and anosmia in 6 (5.4%) patients; however, of those patients self-reporting normal smell but who were found to have hypofunction on testing, 62 out of 66 had self-reported reduction in sense of smell or taste at an earlier time point. Despite most patients report a subjectively normal sense of smell, we observed a high percentage of persistent smell dysfunction at 6 months from the diagnosis of SARS-CoV-2 infection, with 11.7% of patients being anosmic or severely microsmic. These data highlight a significant long-term rate of smell alteration in patients with previous SARS-COV-2 infection.

Keywords: COVID-19; SARS-CoV-2; anosmia; coronavirus; olfactory function; smell and taste loss.
 
Back
Top Bottom